Articles related to EMERGING THERAPIES

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.

PrimeC lowered neuron-derived TDP-43 levels in a Phase 2b ALS trial, with earlier analyses reporting functional and survival signals requiring confirmation in a planned pivotal study.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

The FDA granted Fast Track designation to elunetirom, an oral CNS thyroid hormone receptor agonist, for adjunctive treatment of bipolar depression, while the agent remains in a 30-participant open-label phase 2 trial with no human efficacy data yet available.

Researchers at the National University of Singapore developed a spinach-derived nanotechnology delivering plant photosynthetic machinery into corneal cells via eye drops, demonstrating reversal of corneal damage to near-healthy levels within five days in preclinical models of dry eye disease.